Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial
Year: 2014
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: The Lancet Oncology
Authors: Suresh S Ramalingam, Pasi A Jänne, Tony Mok, Kenneth O'Byrne, Michael J Boyer, Joachim Von Pawel, Adam Pluzanski, Mikhail Shtivelband, Lara Iglesias Docampo, Jaafar Bennouna, Hui Zhang, Jane Q Liang, Jim P Doherty, Ian Taylor, Cecile B Mather, Zelanna Goldberg, Joseph O'Connell, Luis Paz-Ares
Institutions: Emory University, Winship Cancer Institute, Dana-Farber Cancer Institute, Chinese University of Hong Kong, Princess Alexandra Hospital, Royal Prince Alfred Hospital, Chris O’Brien Lifehouse, Asklepios Fachkliniken München-Gauting, The Maria Sklodowska-Curie National Research Institute of Oncology, Hospital Universitario 12 De Octubre, Pfizer (China), Pfizer (United States), Hospital Universitario Virgen del Rocío
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W1984004254